Table 1.
Patients’ clinicopathologic characteristics
| Characteristic | Value (n=866) |
|---|---|
| Age (yr) | 53.5±11.2 |
| BMI (kg/m2) | 23.4±3.4 |
| Co-morbidities | |
| Hypertension | |
| No | 698 (80.6) |
| Yes | 168 (19.4) |
| Diabetes | |
| No | 797 (92.0) |
| Yes | 69 (8.0) |
| Dyslipidemia | |
| No | 803 (92.7) |
| Yes | 61 (7.0) |
| Unknown | 2 (0.2) |
| Pretreatment CBC | |
| Hemoglobin (g/dL) | 12.3±1.3 |
| Platelets (×103/μL) | 327.5±104.2 |
| WBC (×103/μL) | 7.1±2.5 |
| Segmented neutrophils (%) | 66.3±10.1 |
| Count (×10/μL) | 478.4±215.3 |
| Lymphocytes (%) | 24.3±9.0 |
| Count (×10/μL) | 160.2±56.2 |
| Monocytes (%) | 6.9±2.3 |
| Count (×10/μL) | 47.5±23.4 |
| ln(CA-125) (IU/mL) | 5.8±1.9 |
| FIGO stage | |
| I | 220 (25.4) |
| II | 62 (7.2) |
| III | 441 (50.9) |
| IV | 143 (16.5) |
| Histologic type | |
| Serous | 529 (61.1) |
| Endometrioid | 96 (11.1) |
| Mucinous | 79 (9.1) |
| Clear cell | 85 (9.8) |
| Others | 77 (8.9) |
| Primary treatment strategy | |
| PDS | 712 (82.2) |
| NAC | 154 (17.8) |
| Residual tumor after PDS/IDS (cm) | |
| No gross | 638 (73.7) |
| < 1 | 144 (16.6) |
| 1-2 | 44 (5.1) |
| > 2 | 31 (3.6) |
| Unknown | 9 (1.0) |
| Post-operative taxane- and platinum-based chemotherapy | |
| No | 74 (8.5) |
| Yes | 792 (91.5) |
| CRa) | 616 (71.1) |
| PR | 108 (12.5) |
| SD | 13 (1.5) |
| PD | 55 (6.4) |
| Recurrence | |
| No | 425 (49.1) |
| Yes | 441 (50.9) |
| No post-operative chemotherapy | 8 (0.9) |
| PSRb) | 285 (32.9) |
| PRR | 148 (17.1) |
| Platinum sensitivity | |
| Platinum-sensitivec) | 562 (64.9) |
| Platinum-resistant | 148 (17.1) |
Values are presented as mean±standard deviation or number (%). BMI, body mass index; CA-125, cancer antigen 125; CBC, complete blood count; WBC, white blood cell; FIGO, International Federation of Gynecology and Obstetrics; PDS, primary debulking surgery; NAC, neoadjuvant chemotherapy; IDS, interval debulking surgery; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; PSR, platinum-sensitive recurrence; PRR, platinum-resistant recurrence; SD, standard deviation.
Reponses to chemotherapy were evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1,
PSR was defined as relapse ≥ 6 months after completion of taxane- and platinum-based chemotherapy, whereas PRR as relapse < 6 months,
In addition to PSR, the patients who completed taxane- and platinum-based chemotherapy and did not experience disease recurrence during at least 6 months of follow-up period were considered platinum-sensitive.